Logo image of ZIVO

ZIVO BIOSCIENCE INC (ZIVO) Stock Fundamental Analysis

USA - NASDAQ:ZIVO - US98978N3098 - Common Stock

1.1 USD
-0.05 (-4.35%)
Last: 11/24/2023, 8:12:49 PM
1.12 USD
+0.02 (+1.82%)
After Hours: 11/24/2023, 8:12:49 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to ZIVO. ZIVO was compared to 34 industry peers in the Personal Care Products industry. ZIVO may be in some trouble as it scores bad on both profitability and health. ZIVO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year ZIVO has reported negative net income.
In the past year ZIVO has reported a negative cash flow from operations.
In the past 5 years ZIVO always reported negative net income.
In the past 5 years ZIVO always reported negative operating cash flow.
ZIVO Yearly Net Income VS EBIT VS OCF VS FCFZIVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -5M -10M

1.2 Ratios

With a Return On Assets value of -404.76%, ZIVO is not doing good in the industry: 94.87% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -404.76%
ROE N/A
ROIC N/A
ROA(3y)-1550.36%
ROA(5y)-2266.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZIVO Yearly ROA, ROE, ROICZIVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 20K 40K 60K 80K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZIVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZIVO Yearly Profit, Operating, Gross MarginsZIVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -10K -20K -30K -40K

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, ZIVO has about the same amount of shares outstanding.
Compared to 1 year ago, ZIVO has a worse debt to assets ratio.
ZIVO Yearly Shares OutstandingZIVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M
ZIVO Yearly Total Debt VS Total AssetsZIVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

2.2 Solvency

ZIVO has an Altman-Z score of -94.02. This is a bad value and indicates that ZIVO is not financially healthy and even has some risk of bankruptcy.
ZIVO has a worse Altman-Z score (-94.02) than 97.44% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -94.02
ROIC/WACCN/A
WACCN/A
ZIVO Yearly LT Debt VS Equity VS FCFZIVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 0.62 indicates that ZIVO may have some problems paying its short term obligations.
With a Current ratio value of 0.62, ZIVO is not doing good in the industry: 84.62% of the companies in the same industry are doing better.
A Quick Ratio of 0.62 indicates that ZIVO may have some problems paying its short term obligations.
The Quick ratio of ZIVO (0.62) is worse than 71.79% of its industry peers.
Industry RankSector Rank
Current Ratio 0.62
Quick Ratio 0.62
ZIVO Yearly Current Assets VS Current LiabilitesZIVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.67% over the past year.
EPS 1Y (TTM)1.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y85.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZIVO Yearly Revenue VS EstimatesZIVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 200K 400K 600K 800K
ZIVO Yearly EPS VS EstimatesZIVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 -1 -2 -3 -4 -5

0

4. Valuation

4.1 Price/Earnings Ratio

ZIVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZIVO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZIVO Price Earnings VS Forward Price EarningsZIVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZIVO Per share dataZIVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

ZIVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ZIVO BIOSCIENCE INC

NASDAQ:ZIVO (11/24/2023, 8:12:49 PM)

After market: 1.12 +0.02 (+1.82%)

1.1

-0.05 (-4.35%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)N/A N/A
Inst Owners0.01%
Inst Owner Change0%
Ins Owners128.97%
Ins Owner Change0.84%
Market Cap1.91M
Revenue(TTM)10.00K
Net Income(TTM)-8500000
Analysts82.86
Price Target36.72 (3238.18%)
Short Float %3.7%
Short Ratio1.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.84%
Min EPS beat(2)-7.84%
Max EPS beat(2)-7.84%
EPS beat(4)1
Avg EPS beat(4)-8.12%
Min EPS beat(4)-30.72%
Max EPS beat(4)14.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-95.1%
Min Revenue beat(2)-95.1%
Max Revenue beat(2)-95.1%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)500%
PT rev (3m)500%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 191.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.58
EYN/A
EPS(NY)-0.82
Fwd EYN/A
FCF(TTM)-3.75
FCFYN/A
OCF(TTM)-3.75
OCFYN/A
SpS0.01
BVpS-0.63
TBVpS-0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -404.76%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1550.36%
ROA(5y)-2266.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.62
Quick Ratio 0.62
Altman-Z -94.02
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.97%
EPS Next Y85.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.54%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.41%
OCF growth 3YN/A
OCF growth 5YN/A

ZIVO BIOSCIENCE INC / ZIVO FAQ

Can you provide the ChartMill fundamental rating for ZIVO BIOSCIENCE INC?

ChartMill assigns a fundamental rating of 0 / 10 to ZIVO.


Can you provide the valuation status for ZIVO BIOSCIENCE INC?

ChartMill assigns a valuation rating of 0 / 10 to ZIVO BIOSCIENCE INC (ZIVO). This can be considered as Overvalued.


How profitable is ZIVO BIOSCIENCE INC (ZIVO) stock?

ZIVO BIOSCIENCE INC (ZIVO) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ZIVO BIOSCIENCE INC?

The Earnings per Share (EPS) of ZIVO BIOSCIENCE INC (ZIVO) is expected to grow by 85.38% in the next year.